The highest incidence of relapse to smoking occurs within the first 2 weeks of a cessation attempt. In addition to enhanced nicotine craving, this phase of smoking cessation is also marked by learning and memory dysfunction. Many smokers are not able to overcome these symptoms, and they relapse to smoking shortly after trying to quit. In two clinical studies, we evaluated intranasal insulin for efficacy in improving learning and memory function during nicotine withdrawal. Our first study was a crossover evaluation (N = 19) following 20 hr of smoking abstinence. Study 2 was a parallel design study (N = 50) following 16 hr of abstinence. Intranasal insulin (60 IU) dose was administered in both studies and cognitive function was measured using California Verbal Learning Test-II. Intranasal insulin did not improve learning over the 5 verbal learning trials. In addition, intranasal insulin did not improve either short-or long-delay recall in either study. In summary, the one-time administration of intranasal insulin does not improve verbal learning and memory in smokers. Whether longer administration schedules may be of benefit should be evaluated in future studies.
| INTRODUCTION
Many cigarette smokers express a desire to quit smoking; however, rates of relapse to smoking within 1 year after initiating a quit attempt are~90% (Hughes, Goldstein, Hurt, & Shiffman, 1999) , with the highest incidence of relapse occurring within the first 2 weeks (Swan, Ward, Carmelli, & Jack, 1993) . A significant barrier to quitting for many smokers is the tobacco abstinence syndrome, marked by nicotine craving, anxiety, restlessness, and cognitive impairment (Ernst, Heishman, Spurgeon, & London, 2001; Hirshman, Rhodes, Zinser, & Merritt, 2004; Merritt, Cobb, Moissinac, & Hirshman, 2010; Myers, Taylor, Moolchan, & Heishman, 2008) . One important dysfunction, which we studied here, is an impairment in verbal learning and memory during nicotine withdrawal.
Verbal memory function is assessed by a task that involves presentation of a list of words that a subject is asked to recall immediately as well as after a delay. Previous studies have shown that abstinent smokers are impaired in recalling presented words. Evaluating a cohort of adolescent smokers under conditions of ad lib smoking and after 24 hr of abstinence, Jacobsen, Mencl, Constable, Westerveld, and Pugh (2007) have shown a decline in immediate verbal memory under the condition of smoking abstinence. In an additional study involving ad lib smokers, abstinent smokers, and nonsmokers who completed a verbal learning protocol, Soar, Dawkins, Begum, and Parrott (2008) have shown that the impairment in verbal learning associated with smoking abstinence is reversed following smoking resumption. These studies utilized Hopkins Verbal Learning Test-Revised (Jacobsen et al., 2007) and Auditory Verbal Learning Test (Soar et al., 2008) , in which, similarly to the test utilized in this study, a participant first learns a list of words (following the list being presented 5 times) and then recalls it immediately or after a period of delay (i.e., less than 30 min).
Nicotine improves memory function by binding to presynaptic nicotinic acetylcholine receptors in the brain, thereby facilitating the release of acetylcholine, dopamine, serotonin, glutamate, and other neurotransmitters known to be involved in cognitive processes Benowitz (2009) . A meta-analysis, conducted by Heishman, Kleykamp, and Singleton (2010) , has shown that the effect of nicotine on verbal memory is due to its true cognition-enhancing effect, not as part of a more general withdrawal relief. The meta-analysis only included cant systemic absorption and hypoglycemic events. Cerebrospinal fluid insulin in humans peaks 30 min following the intranasal administration without peripheral insulin changes (Born et al., 2002) . In our primary work, we have shown that intranasal insulin relieves nicotine cravings (Hamidovic et al., 2017) . We here report the results of our investigation on intranasal insulin efficacy in improving verbal learning and memory function during nicotine withdrawal.
| METHODS

| Participants
Male and female smokers living in Central New Mexico (18 to 65 years of age) were recruited via advertisement to participate. Subjects were included if they reported smoking ≥10 cigarettes per day for the past year, had normal vitals (blood pressure <140/90, heart rate 50-100 bpm, and body temperature <37.4°C), normal blood glucose 
| Study 1 procedures
Subjects first attended a screening session to ensure study eligibility. Following the screening appointment, subjects were admitted to an inpatient unit for one overnight stay. Subjects reported to the inpatient unit of the University of New Mexico Clinical and Translational Sciences
Center at 1130 h on Day 1 after beginning smoking cessation at 2000 h on the day prior. Following confirmation of overnight smoking abstinence with the CO level being 50% of the level detected at the screening session, subjects provided urine and breath samples to rule out illicit drug use and alcohol consumption. In order to continue with the study session, study participants had to have vitals within normal limits (BP <140/90 mmHg, heart rate between 50 and 100 bpm, and temperature <37.4°C). In addition, as agreed upon with the Food and Drug Administration, study participants had to have a normal olfactory physical exam and a point-of-care (POC) glucose level >70 mg/dl in order to proceed with treatment administration. Spray was administered at 1240 h as one spray in each nostril every 3 min for the total of six sprays.
Lunch was given at 1300 h and California Verbal Learning Test-II (CVLT-II) was administered at 1320 h. The timing of CVLT-II administration was projected to coincide with the peak cerebrospinal fluid insulin level following intranasal administration (Born et al., 2002) . Discharge occurred at 1245 h on Day 2 following administration of additional study tests (published in Hamidovic et al., 2017) . The entire session was 36 hr of abstinence; the CVLT-II testing occurred approximately after 20 hr of abstinence. The two sessions (placebo and insulin, in random order) of this crossover study were separated by approximately 1 week.
| Study 2 procedures
This paper is an analysis of a two-session study evaluating efficacy of intranasal insulin (60 IU). The first session involved an evaluation of learning and memory (details outlined below). The second visit involved participation in a psychosocial stress session. The measures from that session-craving, hormonal, and cardiovascular responsesare published separately in Hamidovic et al. (2017) .
Study subjects attended a screening appointment and an outpatient study session. The screening session included two parts.
First, eligibility criteria-as specified in Section 2.1-was assessed.
Upon completion of the 3.5 hr screening visit, subjects were scheduled for the first of the total of two study sessions. The procedures and results presented here are from the first study session. Participants (n = 50) reported to the outpatient unit of the University of New Mexico Clinical and Translational Sciences Center at 0800 h after beginning smoking abstinence at 2000 h the night prior. Abstinence from smoking was verified with a CO reading on a coVita (Haddonfield, NJ, USA) piCO+ breathalyzer with less than 50% of their baseline CO recorded at intake. A subset of individuals (N = 24 of the sample) had a nicotine level verified by a serum analysis. None of the tested subjects had a detectable nicotine level suggestive of smoking. Following negative urine drug and pregnancy tests, at 0900 h, subjects were provided breakfast (a slice of banana bread, one apple, and two cheese sticks) that they had to eat entirely. The purpose of providing breakfast was to ensure food intake as study participants underwent a fast until the session was completed. The rest of the morning, subjects watched and read emotionally neutral movies and literature.
At 1215 h, a study nurse collected the first blood sample and completed a POC glucose check and nares assessment. As agreed upon with the Food and Drug Administration the purpose of the POC glucose check was to ensure that none of the tested participants were hypoglycemic prior to intranasal insulin administration. At the time of the study, it was not known whether the treatment may cause a drop in blood glucose. In addition, the Food and Drug Administration required that a nares check be performed prior to intranasal insulin administration to rule out inflammation or infection.
Intranasal spray administration of insulin or placebo was carried out at 1230 h as one spray in each nostril every 3 min for the total of six sprays. At 1310 h, CVLT-II was administered at the time projected to reflect peak cerebrospinal fluid insulin levels (Born et al., 2002) . The second blood sample was collected at 1420 h. Study participants were discharged at 1600 h with two POC measurements and a snack between 1420 h and 1600 h. As agreed upon with the Food and Drug Administration, subjects were kept in the lab even though data collection ended to ensure that they would not be sent home in case of a sudden hypoglycemic episode.
| Drug dosing and preparation
Drug compounding occurred at the University of New Mexico Health Sciences Center Translational Pharmacy lab in a biosafety cabinet using aseptic technique per Food and Drug Administration approved protocol. The drug substance used for intranasal insulin was bulk Novolin R (Novo Nordisk, Plainsboro, NJ, USA). Drug preparation occurred within 30 min of administration. The drug was packaged in 10-ml amber glass bottles (Gerresheimer, Dusseldorf, Germany) capped with 10 mg nasal pumps (Aero Pump, Hochheim am Main, Germany). The dose was selected on the basis of a study in Alzheimer's disease patients in which the doses were 20 and 40 IU (Craft et al., 2012) . Though higher doses (160 IU) have been used (Benedict et al., 2004; Benedict, Kern, Schultes, Born, & Hallschmid, 2008) , those doses have been associated with increased circulating insulin immediately following intranasal administration. We avoided administering the high dose of intranasal insulin out of the concern of hypoglycemia. In addition, in the event of both positive results and changes in circulating insulin following intranasal administration, the positive findings cannot solely be attributed to central effects. A full description of drug preparation and administration may be found in our original publication (Hamidovic et al., 2017) .
| California Verbal Learning Test-II adult version
Learning and memory were assessed using the CVLT-II adult version (Delis, Kramer, Kaplan, & Ober, 2000) . The CVLT-II is a neuropsychological test of episodic memory, which involves the oral presentation of a 16-word list (List A) over five immediate-recall trials (Trials 1-5 ).
An interference list (List B) is then presented for one immediate-recall trial (Trial B), followed by free-recall (participant asked to recite as many words as they could remember in any order) of List A (short delay free recall), and a cued recall (participant prompted to recite words from four semantic categories) of List A (short delay cued recall). After a 20-min delay, subjects are asked to free-recall List A (long delay free recall), followed by cued recall of List A (long delay cued recall; see Figure 1 ).
Test administration time was about 45 min, including the 20-min delay interval during which subjects completed questionnaires. Audio FIGURE 1 Graphic presentation of California Verbal Learning Test-II (CVLT-II). List A was read to study participants 5 times. After each List A reading, participants recalled back the words they memorized. List B was a different list (i.e., the "distractor" list) read to participants, which they were asked to repeat. Short delay recall refers to recalling List A words immediately after List B was read to the participants. Long delay refers to recalling List A words after a 20-min break. "Free" recall refers to recalling words without being asked to recall them in a particular categorical order; "cued" recall involves the examiner specifying a particular word category (e.g., "animals"), which served as a cue to subjects recordings for each CVLT-II were used for scoring after the test was completed. Two trained research coordinators listened to the recordings independently and then compared results for accuracy. Discrepancies were relistened by the research coordinators following which the results were synchronized. Scores were reported for Trials 1-5, Trial B, short delay free recall, short delay cued recall, long delay free recall, and long delay cued recall.
| Data analysis
Participant characteristics were compared using t test for continuous and chi-square for categorical variables. All outcome data were tested for distribution normality and skewness. If detected, data were corrected using the lnskew0 STATA command, which performs a log transformation after adding a constant, thus creating a zero skewness logged variable. Before continuing with data analysis, it was first confirmed that this method did indeed correct variable normality and skewness.
Study 1 data analyses were carried out using mixed model analyses. Random coefficient models were constructed for analyzing study outcomes as a combination of fixed and random effects. Learning scores included the number of recalled words (over five trials). Learning was analyzed in a model with treatment, order of treatment administration, trial, and treatment by trial interaction as fixed effects. Trial nested within subject and trial nested within treatment nested within subject were included as random effects. Trial B, short and long delay (both free and cued) analysis models included treatment and baseline scores as fixed effects and treatment nested within subject as random effect.
Study 2 data analysis was carried out using mixed model analyses.
Learning was analyzed in a model with treatment, trial, and treatment by trial interaction as fixed effects. Trial nested within subject was included as random effect. Trial B, short and long delay (both free and cued) analysis models included treatment and baseline scores as fixed effect. Treatment nested within subject was included as a random term.
Sample size was determined a priori using Soar et al. (2008) . The result of that analysis showed an approximate size of 25 participants per group to capture the effect of treatment. One subject CVLT-II data in Study 2 was discarded because the subject had zero words recalled, suggestive of unwillingness to participate in the study procedure.
Data were analyzed using STATA Version 12. The p statistics are reported at their nominal, nonmultiple comparison-corrected value.
| RESULTS
| Subjects
Study 1 basic demographic table is published in Hamidovic et al. (2017) and summarized in table 1 of that manuscript.
Twenty-six of the total of 50 subjects completing Study 2 received intranasal insulin (see Table 1 ). Most participants were White men of middle age who were moderately nicotine dependent; t test and chisquare analyses for continuous and categorical variables (respectively) listed in Table 1 did not reveal any significant group differences. In addition to basic demographic variables, Table 1 also shows lifetime use of illicit drugs by treatment groups.
| Learning
Intranasal insulin did not improve learning in either study as evidenced by a lack of either main effect of treatment or a treatment × trial interaction. As expected, study participants learned new words upon the list being repeated over five trials. The graphical details are displayed in Figures 2 and 3 (left side) for Studies 1 and 2, respectively. Tables 2 and 3 for Studies 1 and 2, respectively.
The details of analytical results are displayed in
| Memory
Intranasal insulin did not improve short-and long-term recall in either study. The graphical details are displayed in Figures 2 and 3 (right side) for Studies 1 and 2, respectively. The details of analytical results are displayed in Tables 4 and 5 for Studies 1 and 2, respectively. The nonsignificant effect of treatment was the case for both free and cued recall.
| DISCUSSION
In summary, intranasal insulin administration did not improve verbal learning or memory in our studies designed on the basis of rigorous clinical trial methodology. Our hypothesis that intranasal insulin would improve these outcomes was based on earlier studies in Alzheimer's showing memory improvements following intranasal insulin treatment (Craft et al., 2012; Craft et al., 2017) .
It could be argued that we did not observe significant effects because they may not be observable after an acute, one-time intranasal insulin administration. This is certainly a possibility because the literature regarding memory task performance following acute intranasal insulin administration is mixed. For example, Reger et al. (2006) found that one intranasal insulin dose (20 IU) caused worse word recall scores, whereas the 40-IU dose caused an improvement in word recall.
Moreover, although Brunner, Kofoet, Benedict, and Freiherr (2015) were able to show that intranasal insulin (40 IU), administered to healthy young men, improved delayed (but not immediate) odor-cued recall of spatial memory, the group (Brunner, Rodriguez-Raecke, Mutic, Benedict, & Freiherr, 2016) was not able to replicate the behavioral data (recalling olfactory or visual cues at different target locations) in a functional brain imaging study.
A recent study (Feld et al., 2016) 2016 study) is a requirement to observe the action of insulin in disrupting interfering information. The other possibility is that the dose we used in our study is inadequate to observe this specific effect.
Efficacy of chronic intranasal insulin seems to be not only diseasespecific but may also reflect medication adherence. Though the study that intranasal insulin improved memory function in Alzheimer's disease dementia or amnesic mild moderate impairment has been replicated (Craft et al., 2012; Reger et al., 2008) , the negative findings of intranasal insulin on other clinical outcomes, including bipolar disorder (McIntyre et al., 2012) , major depressive disorder (Cha et al., 2017) , and schizophrenia (Fan et al., 2013) , need to be evaluated in light of a substantial concern regarding medication adherence in the clinical trials with intranasal insulin. Currently, intranasal insulin is formulated with the commercially available insulin designed for subcutaneous administration. In our studies (Hamidovic et al., 2017) , we have shown that intranasal insulin causes substantial pain and burning, and others (Lehrer, 2015) have called for reformulation of intranasal insulin. Medication adherence is a problem for all clinical trials, but the degree of its interference in the outcome of trials with intranasal insulin needs to be carefully evaluated.
FIGURE 2 Graphic presentation of California Verbal Learning Test-II performance in Study 1. The study (N = 19) was a crossover evaluation of intranasal insulin (60 IU) versus placebo. Participants were tested after 20 hr of smoking abstinence. Intranasal insulin had no effect on learning (Trials 1-5), Trial B (distractor trial), or any of the four recall trials as listed in the figure   FIGURE 3 Graphic presentation of California Verbal Learning Test-II performance in Study 2. The study was a parallel evaluation (N = 50) of intranasal insulin (60 IU) versus placebo. Participants were tested after 16 hr of smoking abstinence. As in Study 1, intranasal insulin had no effect on learning (Trials 1-5), Trial B (distractor trial), or any of the four recall trials as listed in the figure The main limitation of our study is a lack of nonabstinence condition. It is not known whether participants in our study experienced a decline in verbal learning and memory. However, numerous studies have shown that abstinent smokers are impaired in recalling presented words immediately as well as after a delay (Dunbar et al., 2007; Foulds et al., 1996; Krebs, Petros, & Beckwith, 1994; Merritt et al., 2010; Merritt, Cobb, & Cook, 2012; Soar et al., 2008; Wesnes, Edgar, Kezic, Salih, & de Boer, 2013) . Though our study was a single-blind in design, participants were not aware of the treatment. Our placebo was compounded as 8.7% sodium chloride, which produced similar level of pain and burning (Hamidovic et al., 2017) , thereby masking participants' awareness of treatment received.
In conclusion, our rigorous clinical trial methodology studies showed no effect of intranasal insulin on learning and memory functions. These studies involved acute administration of intranasal insulin, which may be different from central insulin's effects observed following a long-term administration.
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